Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit
Open Access
- 18 June 2010
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 85 (4), 335-344
- https://doi.org/10.1111/j.1600-0609.2010.01491.x
Abstract
Cardiac complications because of transfusional iron overload are the main cause of death in thalassaemia major. New chelators and iron monitoring methods such as cardiac magnetic resonance (CMR) became available after the year 2000. We evaluated the impact of these new management options on cardiac mortality and morbidity. The risk of cardiac death during 1990–1999 and 2000–2008 was compared. Furthermore, after 1999, morbidity, mortality and reversal of heart failure were evaluated according to chelation regime: desferrioxamine (DFO), deferiprone (DFP) and combination therapy of DFO and DFP. We also present preliminary results for deferasirox (DFX), a new oral chelator. Three hundred and fifty-four patients were included in the de novo cardiac event evaluation, while 86 were included in the improvement component. The annual risk of cardiac death in patients aged between 20–30 and 30–40 reduced from 1.52% to 0.67% and 1.87% to 0.56%, respectively, before and after the year 2000. The risk for a de novo cardiac event for DFO was 9.1 times greater than that of DFP and 23.6 than with the combination of DFP and DFO. For DFX, there was one cardiac event over 269 patient-years. The risk of cardiac death was 9.5 per 1000 patient-years for DFO, 2.5 on DFP, 1.4 on combination. In the DFX group no cardiac deaths were recorded. The odds of improvement were 8.5 times greater with DFP and 6.1 with combination therapy compared to DFO. The new chelation regimes, together with CMR have contributed significantly to the reduction in cardiac morbidity and mortality in patients with thalassaemia major.Keywords
This publication has 31 references indexed in Scilit:
- Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek UnitEuropean Journal of Haematology, 2009
- Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesBMC Medical Genomics, 2009
- The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational studyJournal of Cardiovascular Magnetic Resonance, 2009
- Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2008
- Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJournal of Cardiovascular Magnetic Resonance, 2008
- Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood, 2006
- Longitudinal Study of Survival and Causes of Death in Patients with Thalassemia Major in GreeceAnnals of the New York Academy of Sciences, 2005
- Reversal of heart failure in thalassemia major by combined chelation therapy: a case reportEuropean Journal of Haematology, 2004
- Complications of β-thalassemia major in North AmericaBlood, 2004
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000